Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene
MYC dosage compensation is mediated by miRNA-transcription factor interactions in aneuploid cancer.
Acon M, Geiss C, Torres-Calvo J, Bravo-Estupinan D, Oviedo G, Arias-Arias JL, Rojas-Matey LA, Edwin B, Vasquez-Vargas G, Oses-Vargas Y, Guevara-Coto J, Segura-Castillo A, Siles-Canales F, Quiros-Barrantes S, Regnier-Vigouroux A, Mendes P, Mora-Rodriguez R
iScience. 2021 Nov 8;24(12):103407. doi: 10.1016/j.isci.2021.103407. eCollection 2021 Dec 17. PubMed Article

Plasmids from Article

ID Plasmid Purpose
176892pSBbi-moxGFP-P2A-T2A-cMyc-PuroSleeping Beauty transposon-based vector for mammalian polycistronic expression of moxGFP, c-Myc and an additional gene of interest
176893pSBbi-moxGFP-P2A-T2A-Puro Sleeping Beauty transposon-based vector for mammalian polycistronic expression of moxGFP and two additional genes of interest

Antibodies from Article